Analysts Set Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Price Target at $22.14

Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) have received a consensus recommendation of “Buy” from the nine ratings firms that are currently covering the firm, MarketBeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $22.14.

Several research firms have recently weighed in on LXEO. Royal Bank of Canada restated an “outperform” rating and set a $24.00 price target on shares of Lexeo Therapeutics in a report on Tuesday, August 13th. Chardan Capital reissued a “buy” rating and set a $23.00 target price on shares of Lexeo Therapeutics in a report on Friday, October 25th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $21.00 price target on shares of Lexeo Therapeutics in a research note on Thursday, October 31st.

Insider Buying and Selling at Lexeo Therapeutics

In other news, CEO Richard Nolan Townsend sold 5,000 shares of the business’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $10.65, for a total value of $53,250.00. Following the transaction, the chief executive officer now directly owns 120,695 shares of the company’s stock, valued at $1,285,401.75. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last quarter, insiders have sold 15,000 shares of company stock valued at $151,400. 4.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Lexeo Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in LXEO. RA Capital Management L.P. bought a new position in Lexeo Therapeutics in the first quarter worth approximately $10,364,000. Janus Henderson Group PLC raised its position in shares of Lexeo Therapeutics by 9.0% during the first quarter. Janus Henderson Group PLC now owns 2,540,785 shares of the company’s stock worth $39,802,000 after purchasing an additional 210,047 shares during the period. Artal Group S.A. lifted its holdings in shares of Lexeo Therapeutics by 32.9% in the 1st quarter. Artal Group S.A. now owns 801,716 shares of the company’s stock worth $12,571,000 after purchasing an additional 198,281 shares in the last quarter. Vanguard Group Inc. increased its stake in Lexeo Therapeutics by 15.8% during the 1st quarter. Vanguard Group Inc. now owns 481,755 shares of the company’s stock valued at $7,554,000 after purchasing an additional 65,573 shares in the last quarter. Finally, Values First Advisors Inc. acquired a new position in Lexeo Therapeutics during the third quarter worth $67,000. Institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Stock Performance

NASDAQ:LXEO opened at $7.89 on Friday. The company has a market cap of $260.84 million and a price-to-earnings ratio of -0.54. Lexeo Therapeutics has a fifty-two week low of $7.54 and a fifty-two week high of $22.33. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.38 and a current ratio of 9.38. The stock has a fifty day moving average price of $9.45 and a 200-day moving average price of $12.43.

Lexeo Therapeutics (NASDAQ:LXEO) last released its earnings results on Monday, August 12th. The company reported ($0.64) earnings per share for the quarter, hitting the consensus estimate of ($0.64). As a group, equities analysts anticipate that Lexeo Therapeutics will post -2.76 EPS for the current fiscal year.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.